ArticleOncology letters2025

PD‑1/PD‑L1 inhibitor‑based immunotherapy in locally advanced or metastatic triple‑negative breast cancer: A meta‑analysis.

Yonghui Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.